Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc (BRNS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BRNS · as of Jun 9, 2026
Key Statistics
Explore Barinthus Biotherapeutics plc Data
brns stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
The BRNS analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $3.00, representing +316.67% upside from the current price of $0.72.
Competitors & Peers
brns competitorsBRNS
ALGS
CVM
INMB
KPTI
KZRStock Performance
Full HistoryAbout Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's…
what is barinthus biotherapeutics plc · brns stock overview · barinthus biotherapeutics plc company profile · who is barinthus biotherapeutics plc ceo · brns NASDAQ · barinthus biotherapeutics plc headquarters · barinthus biotherapeutics plc business segments
About Stock Overview & Key Data
Barinthus Biotherapeutics plc (BRNS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 30, 2021. As of the latest trading session, BRNS stock price is $0.72, with a market capitalization of $29.4M. The stock has returned -27.30% over the past 12 months and +2.84% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Barinthus Biotherapeutics plc stock is Buy, with an average 12-month price target of $3.00. In fiscal year 2025, Barinthus Biotherapeutics plc reported revenue of — and net income of -$66.6M. For detailed data — including Barinthus Biotherapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Barinthus Biotherapeutics plc (BRNS) stock price is $0.72. The stock is traded on NASDAQ under the ticker symbol BRNS. The 52-week range is $0.51 – $2.92.